Martine Zimmermann - 06 Jun 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Martine Zimmermann
Issuer symbol
LGND
Transactions as of
06 Jun 2025
Net transactions value
-$19,926
Form type
4
Filing time
10 Jun 2025, 19:21:57 UTC
Previous filing
18 Jun 2024
Next filing
24 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Zimmermann Martine Director 555 HERITAGE DRIVE, SUITE 200, JUPITER By: /s/ Andrew Reardon, Attorney-in-Fact For: Martine Zimmermann 10 Jun 2025 0001994049

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +1,209 +34% $0.000000 4,746 06 Jun 2025 Direct F1
transaction LGND Common Stock Tax liability $19,926 -188 -4% $105.99 4,558 06 Jun 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Award $0 +5,783 $0.000000 5,783 06 Jun 2025 Common Stock 5,783 $105.99 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.
F3 Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.